ArticleCost effectiveness and resource allocation : C/E2026
Cost-utility analysis of free HPV immunization for girls in Rajasthan, India.
Article in Cost effectiveness and resource allocation : C/E, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis paper aims to analyze the cost-utility of implementing a government policy to vaccinate adolescent girls (aged 11 years) against Human Papillomavirus (HPV) for free in the state of Rajasthan in India, compared to the current scenario where the HPV vaccination is not part of the state immunization scheme.
methodsA static, decision-analytic Markov model was used to determine the costs and QALYs associated with the intervention and comparator therapies (arms), necessary to calculate the Incremental Cost-Effectiveness Ratio (ICER) from the payer perspective, in this case, the Rajasthan state-funded healthcare perspective. The model parameters were taken from existing studies and expert opinions. Uncertainties in the model were addressed by conducting a sensitivity analysis.
resultsGiven the costs and the QALYs gained for the model, the intervention of introducing free HPV immunization in Rajasthan is a cost-effective measure with an ICER of -$9548.24/QALY (8,37,822 INR/QALY). Considering all the uncertainties associated with the model, the intervention is not just cost-effective, but cost-saving as well, at a willingness-to-pay threshold of one or three times the Net State Domestic Product (NSDP) per capita of the state of Rajasthan.
conclusionOverall, the program’s high cost-effectiveness indicates that HPV immunization should be explored at a national level, addressing the evidence gaps identified in this study. Because it is extremely cost-effective to introduce an HPV immunization program for girls in the state of Rajasthan, it serves as a scalable model in similar geo-demographic regions. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.